Abstract: Modafi nil, a wakefulness-promoting agent unrelated to classical sympathomimetic stimulants, has been studied in a total of 933 children and adolescents as a treatment for attentiondefi cit/hyperactivity disorder (ADHD). Several studies, including three double-blind, placebocontrolled studies with intent-to-treat analyses, have demonstrated the effi cacy of modafi nil fi lm-coated tablets in reducing symptoms of ADHD and associated problem behaviors in children and adolescents. Modafi nil is generally well tolerated, with adverse events (such as insomnia, headache, loss of appetite, weight loss, and gastrointestinal discomfort) that are generally mild to moderate, rarely leading to medication discontinuation. To minimize treatment-emergent side effects, titration to the target dose of 355-425 mg once a day should take place over 2-3 weeks. Due to reports of skin rash (including one case of possible erythema multiforme/Stevens Johnson Syndrome during pivotal studies), additional studies have been requested to better evaluate the risks of developing severe cutaneous adverse reactions.
Pharmacological management of children and adolescents with attention-defi cit/hyperactivity disorder (ADHD) often results in improvements in symptoms of inattention (distractibility, forgetfulness, inability to concentrate), in symptoms of hyperactivityimpulsivity (restlessness, fi dgetiness, impulsive responses), and in overall quality of life (Brown et al 2005; King et al 2006) . Sympathomimetic stimulants are the most common treatment for ADHD (Brown et al 2005; Arnsten 2006 ), but a sizable minority of children and adolescents with ADHD do not respond adequately to these medications or have intolerable side-effects (Brown et al 2005; King et al 2006) . Thus, additional treatments for ADHD are sought. Modafi nil has been evaluated as a potentially effective medication in reducing problematic symptoms of ADHD.
Molecular and biologic characteristics of modafi nil
Modafi nil (Provigil ® , Cephalon, Inc., Frazer, PA, USA) is a wakefulness-promoting medication that is structurally different from the classical stimulants (methylphenidate, amphetamines, and pemoline; see Figure 1 ). Besides being structurally unique, the neurophysiological properties of modafi nil are also unique in comparison with sympathomimetic stimulants (Lin et al 1992 (Lin et al , 1996 Simon et al 1995; Shelton et al 1995; Ferraro et al 1997) . Besides a low affi nity for the dopamine reuptake carrier site with only a slight increase in extracellular dopamine (Mignot et al 1994) , modafi nil does not bind to nor does it have signifi cant agonist or antagonist activity at any of the known CNS neuronal catecholamine, cholinergic or amino acid/neuropeptide receptors or transporters (Cephalon 2006) . In contrast to the sympathomimetic stimulants, physiological effects of modafi nil are not a direct result of dopaminergic or noradrenergic activity (Akaoka et al 1991; DeSereville et al 1994; Ferraro et al 1997) .
Whereas methylphenidate and amphetamine stimulants have a wide distribution of direct neuronal activity throughout the cortex, basal ganglia, and nucleus accumbens, preclinical studies of modafi nil demonstrate more limited binding, primarily in the hypothalamus (Lin et al 1996) . Increased neuronal activity (as evidenced by increased c-fos activity) was found primarily in orexin neurons of the tuberomammilary nucleus, even with administration of low doses of modafi nil (Scammell et al 2000) . This area of the brain is implicated in regulating physiologic wakefulness (Chemelli et al 1999; Scammell et al 2000) . Evidence also exists for inhibition of the sleep-promoting neurons of the ventrolateral preoptic nucleus after modafi nil adminstration (Gallopin et al 2004) .
Notable in these preclinical studies is the lack of signifi cant activity in the nucleus accumbens (Lin et al 1996; Ferraro et al 1997; Scammell et al 2000) , the brain's reward/ reinforcement center (which mediates most of the addictive properties of drugs such as cocaine, opioids, and stimulants). Several studies have confi rmed the low abuse potential of modafi nil (Deroche-Gamonet et al 2002; Myrick et al 2004) , with less cocaine-like discriminative-stimulus effects and self-reported stimulant effects than methylphenidate or amphetamines (Gold 1996; Jasinski 2000; Jasinski and Lovacevic-Ristanovic 2000; Rush et al 2002a, b) .
Although approved by the US Food and Drug Administration for improving wakefulness in adults with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea, and shift work sleep disorder 16 years of age and older (Cephalon 2004) , its mechanism of action in humans is not fully understood. After administration of modafi nil, functional MRI (fMRI) has shown activation of the anterior cingulate cortex during a task of working memory (Spence et al 2005) , and an activation of other cortical areas (particularly in individuals with low initial activation levels; Ellis et al 1999) . This is very signifi cant, considering that the anterior cingulate cortex was notably defi cient in fMRI activity in individuals with ADHD during a working memory task (Bush et al 1999) . A likely hypothesis regarding modafi nil's physiologic effects is that modafi nil indirectly activates the cerebral cortex (including areas implicated in ADHD pathology) via ascending arousal pathways arising from the hypothalamus (eg, the tuberomammillary nucleus; see Figure 2 ).
Modafi nil is well absorbed from the gastrointestinal tract, but bioavailability cannot he determined since low water solubility makes i.v. administration unfeasible (Cephalon 2004 (Cephalon , 2006 . Peak levels are seen at 2-4 hours after oral administration, but about 1 hour later if administered with food (Cephalon 2004 (Cephalon , 2006 . Metabolized by several cytochrome P450 (CYP450) enzymes, modafi nil is a mild inducer of Modafi nil fi lm-coated tablets for ADHD CYP1A2, CYP2B6, CYP3A4, and is a mild inhibitor of CYP2C19 (Cephalon 2004) . Therefore, interactions with medicines may be seen with diazepam, propranolol, phenytoin, S-mephenytoin, and tricyclic or some SSRI antidepressants (in poor metabolizers of CYP2D6), whereas decreased effi cacy of added medicines may be seen with cyclosporine and birth control hormones (Cephalon 2004) . Strong CYP3A4 inducers (such as carbamazepine, phenobarbital, and rifampin) or inhibitors (such as ketoconazole or itraconazole) may slightly alter modafi nil blood levels (Cephalon 2004) . Half-life in adults is approximately 15 hours, but is shorter for children and adolescents. For children 6-7 years of age, the half-life is about 7 hours (Cephalon 2006) . The halflife gradually lengthens until 9-11 years, when a pronounced shift is seen approaching adult levels (Cephalon 2006) .
Effi cacy in children and adolescents with ADHD
After two investigator-initiated independent studies suggested possible effi cacy of modafi nil in children with ADHD (Rugino and Copley 2001; Rugino and Samsock 2003) , a phase 2 study of 248 children and adolescents aged 6-13 years was completed to determine if divided doses were effective, tolerated, and necessary to treat children with ADHD. The subjects who received 300 mg once per day showed consistently greater improvement in home and school ADHD Rating Scale IV (ADHD-RS-IV; DePaul G, et al 1998) total scores as well as in Conners Parent Rating Scales (CPRS; Connors 1997) ADHD DSM-IV total scores, whereas subjects who received 300 mg per day in divided doses showed less consistent improvements in ADHD symptoms (Biederman et al 2006b) . The pharmacokinetic data from this and other phase 2 studies allowed for computer modeling of the exposure -response relationship. Using a target range for the area under the plasma drug concentration versus time curve (AUC 0-24 ) of 150 μg × hours/mL, doses of 340 mg/day were found to be the most appropriate target dose if the child's weight was <30 kg and 425 mg/day if the child's weight was ≥30 kg (Cephalon 2006) .
Three phase 3 studies involving a total of 638 children and adolescents with ADHD aged 6 to 17 years confi rmed the clinical effi cacy of 85 mg modafi nil fi lm-coated compressed tablets when administered as once-daily doses of up to 340-425 mg over 7-9 weeks (Biederman et IV), and severity of illness was confi rmed with scores ≥1.5 standard deviations above the age-and gender-based mean on the ADHD-RS-IV: School Version. Mental impairment, uncontrolled psychological comorbidity, and signifi cant medical problems excluded subjects from these studies. As is observed in most ADHD studies involving children and adolescents, most of the subjects of these studies (Biederman et al 2005; Swanson et al 2006; Greenhill et al 2006) had ADHD, Combined Type (59%-71%), were male (2.4-2.7:1), and were moderately to markedly ill (82%-91%).
Two fl exible-dose studies (Biederman et al 2005; Greenhill et al 2006) and one fi xed-dose study documented effi cacy of a fi lm-coated compressed tablet formulation of modafi nil using an intent-to-treat analysis with 2:1 ratio of treatment: control and with the endpoint defi ned as the last obtained value carried forward. In the fl exible-dose studies, the mean and modal stable doses were 361-369 mg/day and 425 mg/day (range 170-425 mg once daily every morning), whereas the fi nal administered dose in the fi xed-dose study was 340 mg for children <30 kg and 425 mg for subjects ≥30 kg. For all three studies and for pooled data (Cephalon 2006) , ADHD-RS-IV scores demonstrated improvements consistently in favor of modafi nil for the primary outcome measure (the School Version of the ADHD-RS-IV, see Figures 3a, b, c) , the Home Version of the ADHD-RS-IV, as well as for the inattentive and hyperactive-impulsive subscale scores of each version. There were no effects of race, sex, weight, ADHD subtype, or comorbidity in the improvements seen with modafi nil treatment (Cephalon 2006) . More improvement was seen in patients less than 12 years of age compared with older patients. Modafi nil was effi cacious in treating both stimulant-naïve patients and those who had received prior stimulant therapy. ADHD-RS-IV: School Version total scores showed a reduction of ≥30% in 64%-69% of modafi nil-treated subjects (as compared with 35%-39% of controls, p < 0.0001) and a reduction of ≥50% for 44%-48% of modafi nil-treated subjects as compared with 19%-20% of controls, p < 0.001) for each of the studies (Biederman et al 2005; Swanson et al 2006; Cephalon 2006; Greenhill et al 2006) . Using the ADHD-RS-IV: School Version total score data and Cohen's calculations, the overall pooled effect size was 0.69; this corresponds to a mediumto-large effect (Cohen 1988) . The greatest effect was seen in drug-naïve subjects, in whom the calculated effect size was 1.08 (treatment n = 221 and control n = 102).
For all three of these double-blind, placebo-controlled studies (Cephalon 2006) , the ADHD Rating Scale-IV scores continued to improve while subjects were followed weekto-week (see Figure 3) . Nonetheless, improvements were often seen at the fi rst follow-up visit (week 1 of treatment; Swanson et al 2006; Greenhill et al 2006) . Figure 4 outlines the Clinical Global Impression of Change ratings from these studies (Cephalon 2006) , defi ning a clinical response as "very much improved" or "much improved." Patients treated with modafi nil showed greater improvement in overall clinical condition than those receiving placebo at all study visits and for the last observation carried forward (46% vs 18%). Based on the pooled data (Cephalon 2006) , the number needed to treat was 3.5 (95% confi dence interval = 2.8-4.7). 
Safety and tolerability
The 7-week fi xed-dose study was followed by an abrupt double-blind, placebo-controlled 2-week withdrawal from treatment . No withdrawal symptoms, rebound exacerbation of ADHD symptoms, or rebound hypersomnolence was reported from the subjects who were abruptly withdrawn from modafi nil. During the three cited double-blind, placebo-controlled studies (Biederman et al 2005; Swanson et al 2006; Greenhill et al 2006) , 420 subjects received modafi nil treatment; 55% of subjects had at least one treatment-related adverse event, as compared with 29% of control patients (Cephalon 2006) . Since the fl exible-dose studies (Biederman et al 2005; Greenhill et al 2006) proceeded with a slower upward titration (over the course of 3 weeks) than the fi xed-dose study (over the course of 7-9 days; Swanson 2006), and since the fl exible-dose studies halted upward titration when adequate effi cacy was determined, the frequency of adverse events was lower in the fl exible dose studies than in the fi xed dose study. In each of the fl exible dose studies (Biederman et al 2005; Greenhill et al 2006) , modafi nil-treated patients did not discontinue the study because of an adverse event at a rate higher than placebo, whereas more modafi nil-treated subjects discontinued the study for an adverse event than control subjects (10% vs 0%) in the fi xed dose study . Table 1 describes the adverse events that occurred in at least 5% of the modafi nil-treated patients and that occurred more frequently than in the control group (Cephalon 2006) . When analyzing the pooled data (Cephalon 2006) , Seventyfi ve percent of the adverse events developed within the fi rst 2 weeks of treatment (during upward dose titration). Insomnia was the most frequent adverse event (Biederman et al 2005; Swanson et al 2006; Cephalon 2006; Greenhill et al 2006) , was described as severe in 9 cases and resulted in discontinuation of modafi nil in 5 cases. Insomnia, headache, and gastrointestinal concerns (loss of appetite or abdominal pain) were the most common adverse events that resulted in discontinuation, but fever and nervousness were also rare causes for discontinuation (Biederman et al 2005; Swanson et al 2006; Cephalon 2006; Greenhill et al 2006) . Anorexia/decreased appetite was reported in 16% of subjects (Biederman et al 2005; Swanson et al 2006; Cephalon 2006; Greenhill et al 2006) and was associated with a 0.7 kg decrease of body weight during the 7-9 weeks of treatment of the three phase 3 studies (compared with the control group that gained 1 kg during the same time period). However, during a 12 month open-label extension study (Cephalon 2006 ) that followed the phase 3 studies, the weight z scores (compared with the norms established by the National Center for Health Statistics; Kucsmanski et al 2000) indicated that the subjects were heavier than average at baseline, and the z scores stabilized after 3 months of treatment. On the other hand, height z scores did not appear to decline over the 12-month extension period (Cephalon 2006) .
No signifi cant changes in resting heart rate, resting blood pressure, or electrocardiographic fi ndings were found with administration of modafi nil in doses from 85 mg to 425 mg (Biederman et al 2005; Swanson et al 2006; Cephalon 2006; Greenhill et al 2006) .
Among all children and adolescents who were administered modafi nil as a part of clinical studies for ADHD (n = 933; Cephalon 2006), a total of 18 serious adverse events were described. Of these, only two were reported as "probably" or "possibly" related to modafi nil: a maculopapular/morbiliform rash and a case of possible erythema multiforme/Stevens-Johnson Syndrome (Biederman et al 2005) . All of these skin lesions resolved without sequelae (Cephalon 2006) . Six additional subjects (n = 933) discontinued modafi nil treatment for concerns of rash, with resolution Cephalon 2006). Post-marketing experience was reviewed in light of these skin concerns. Five reports of severe cutaneous adverse reactions have been made since 1999, during which time approximately 673,000 adults have taken modafi nil worldwide (Cephalon 2006) . Further studies evaluating the relationship between the skin rashes and modafi nil/modafi nil sulfone have been requested by the United States Food and Drug Administration.
Psychiatric adverse events, such as aggression, suicidal ideation, and psychosis/mania were recently reported to be consequences of the various medications used to treat ADHD (Gelpirin 2006) . In double-blind and open-label studies for children and adolescents with ADHD (n = 933, Cephalon 2006), aggression was reported for 1.4 to 1.8% of subjects taking modafi nil. A total of 5 subjects reported symptoms of psychosis/mania (one of whom required hospitalization) and 5 reported transient suicidal ideation (most of whom had resolution despite continuing modafi nil treatment). As observed with other ADHD treatments (Celpirin 2006),
Figure 4c
Percentage responders as a function of time for a fi xed-dose study of effi cacy of modafi nil for children and adolescents with attention-defi cit/hyperactivity disorder (n = 183). Response is defi ned as having a Clinical Global Impressions of Change score of 1 ("very much improved") or 2 ("much improved"). *p values <0.05; EP = endpoint, which represents the last obtained value carried forward. Reproduced from Cephalon, Inc. 2006 many of these subjects had no prior remarkable history of similar events.
Conclusion
Modafi nil, when titrated to effect with a target dose of 340 mg (body weight <30 kg) or 425 mg (body weight ≥30 kg) over the course of 2-3 weeks, is effective in managing the symptoms of and the problem behaviors associated with attention-defi cit/hyperactivity disorder in children and adolescents. It is generally well tolerated, with adverse events (such as insomnia, headache, loss of appetite, weight loss, and gastrointestinal discomfort) generally being mild to moderate (and rarely leading to medication discontinuation). Close observation (especially during the fi rst 4 weeks of treatment) may be necessary to watch for the development of a skin rash.
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